Iressa price issue: a signal for drug price slashing policy?

The price down of Iressa, a lung cancer drug, is now on a hot dispute among the MOHW, the civil health/medical groups and AZ company where is claiming that its price reduction has lack of justification.

AZ won the administrative lawsuit for an interim injunction against the price slash, for which the MOHW and the civil health/medical groups indicated an immediate appeal to a high court and a...